CY1119653T1 - Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης - Google Patents

Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης

Info

Publication number
CY1119653T1
CY1119653T1 CY20171101163T CY171101163T CY1119653T1 CY 1119653 T1 CY1119653 T1 CY 1119653T1 CY 20171101163 T CY20171101163 T CY 20171101163T CY 171101163 T CY171101163 T CY 171101163T CY 1119653 T1 CY1119653 T1 CY 1119653T1
Authority
CY
Cyprus
Prior art keywords
sensitivity
terminative
patient
identifying
therapy
Prior art date
Application number
CY20171101163T
Other languages
English (en)
Inventor
Calvin B. Harley
Laurence Elias
Jennifer Smith
Mark J. Ratain
Fabio Benedetti
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of CY1119653T1 publication Critical patent/CY1119653T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Η εφεύρεση παρέχει μεθόδους για τον προσδιορισμό της ευαισθησίας ασθενών με καρκίνο, στην ανάπτυξη ανεπιθύμητων αντιδράσεων, εάν υποβληθούν σε θεραπεία με φάρμακο αναστολέα της τελομεράσης, με μέτρηση του μήκους του τελομερούς στα κατάλληλα κύτταρα του ασθενούς, πριν την έναρξη της θεραπείας με αναστολέα τελομεράσης.
CY20171101163T 2008-10-17 2017-11-07 Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης CY1119653T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10649108P 2008-10-17 2008-10-17
EP09821131.1A EP2342360B1 (en) 2008-10-17 2009-10-13 Method for identification of sensitivity of a patient to telomerase inhibition therapy

Publications (1)

Publication Number Publication Date
CY1119653T1 true CY1119653T1 (el) 2018-04-04

Family

ID=42106854

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100171T CY1117234T1 (el) 2008-10-17 2016-03-01 Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης
CY20171101163T CY1119653T1 (el) 2008-10-17 2017-11-07 Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100171T CY1117234T1 (el) 2008-10-17 2016-03-01 Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης

Country Status (15)

Country Link
US (7) US8877723B2 (el)
EP (4) EP2342360B1 (el)
CY (2) CY1117234T1 (el)
DK (2) DK2342360T3 (el)
ES (4) ES2645872T3 (el)
HK (2) HK1224341A1 (el)
HR (2) HRP20160067T1 (el)
HU (2) HUE027213T2 (el)
LT (1) LT3029154T (el)
NO (1) NO3029154T3 (el)
PL (2) PL2342360T3 (el)
PT (3) PT3719139T (el)
SI (2) SI2342360T1 (el)
SM (1) SMT201600087B (el)
WO (1) WO2010045245A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2925889T (pt) * 2012-11-30 2018-12-12 Geron Corp Marcadores de diagnóstico para o tratamento de transtornos da proliferação celular com inibidores da telomerase
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5741677A (en) 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
EP0870055B1 (en) 1995-10-12 2007-05-16 LANSDORP, Peter, M. Method for detecting multiple copies of a repeat sequence in a nucleic acid molecule
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
EP0951568A1 (en) 1996-12-20 1999-10-27 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
DE69909246D1 (de) * 1998-02-04 2003-08-07 Univ Texas Hemmung der menschlichen telomerase durch g-quadruplex interaktionverbindung
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
KR20070112295A (ko) 1999-09-10 2007-11-22 제론 코포레이션 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP2003534292A (ja) 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US9777312B2 (en) * 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
ATE534746T1 (de) 2002-01-31 2011-12-15 Univ Utah Amplifizieren repetitiver nukleinsäuresequenzen
US20040234961A1 (en) 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
US9169516B2 (en) 2003-01-24 2015-10-27 University Of Utah Research Foundation Methods of predicting mortality risk by determining telomere length
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
HUE054463T2 (hu) 2004-07-02 2021-09-28 Geron Corp Védett 3'-amino 5'-foszforamidit nukleozid monomerek szintézise
DE102005024834B3 (de) 2005-05-31 2007-01-04 Lucas Automotive Gmbh Verfahren und System zur Steuerung einer Kraftfahrzeug-Feststellbremse während eines Halts
JP5177429B2 (ja) * 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
US20070160577A1 (en) * 2005-12-06 2007-07-12 Wyeth Interleukin-11 compositions and methods of use
ES2407957T3 (es) * 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
US20100291560A1 (en) 2007-03-27 2010-11-18 The Johns Hopkins University Methods and compositions for diagnosis and treatment of dyskeratosis congenita and related disorders
WO2009073751A2 (en) 2007-12-04 2009-06-11 Geron Corporation Hair follicle pharmacodynamic assay for telomerase activity
US20090298709A1 (en) 2008-05-28 2009-12-03 Affymetrix, Inc. Assays for determining telomere length and repeated sequence copy number
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
PT2925889T (pt) 2012-11-30 2018-12-12 Geron Corp Marcadores de diagnóstico para o tratamento de transtornos da proliferação celular com inibidores da telomerase

Also Published As

Publication number Publication date
PT3330383T (pt) 2020-05-06
ES2645872T3 (es) 2017-12-11
US20110263685A1 (en) 2011-10-27
EP2342360A4 (en) 2012-10-03
US20220325327A1 (en) 2022-10-13
US20190382829A1 (en) 2019-12-19
WO2010045245A1 (en) 2010-04-22
HRP20160067T1 (hr) 2016-03-25
US10196677B2 (en) 2019-02-05
EP2342360A1 (en) 2011-07-13
SMT201600087B (it) 2016-07-01
EP3719139B1 (en) 2022-11-30
EP3719139A1 (en) 2020-10-07
EP3330383B1 (en) 2020-02-12
US20230114322A1 (en) 2023-04-13
NO3029154T3 (el) 2018-03-03
EP3029154A1 (en) 2016-06-08
HUE037447T2 (hu) 2018-08-28
PT3029154T (pt) 2017-12-06
HUE027213T2 (en) 2016-10-28
PL3029154T3 (pl) 2018-03-30
SI2342360T1 (sl) 2016-04-29
PL2342360T3 (pl) 2016-06-30
PT3719139T (pt) 2023-03-06
US20150152488A1 (en) 2015-06-04
EP3029154B1 (en) 2017-10-04
CY1117234T1 (el) 2017-04-05
DK2342360T3 (en) 2016-04-11
ES2566338T3 (es) 2016-04-12
ES2789580T3 (es) 2020-10-26
SI3029154T1 (en) 2018-02-28
DK3029154T3 (en) 2017-12-11
US9617583B2 (en) 2017-04-11
ES2939509T3 (es) 2023-04-24
HK1224341A1 (zh) 2017-08-18
US20170298421A1 (en) 2017-10-19
US20210269861A1 (en) 2021-09-02
HK1256479A1 (zh) 2019-09-27
LT3029154T (lt) 2017-12-27
HRP20171536T1 (hr) 2018-01-26
EP2342360B1 (en) 2016-01-06
US8877723B2 (en) 2014-11-04
EP3330383A1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
CY1119653T1 (el) Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1118530T1 (el) Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1124281T1 (el) Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
CY1122557T1 (el) Μορια αντι-gcc αντισωματος και χρηση αυτων στη δοκιμη για επιδεκτικοτητα σε θεραπεια στοχευμενη σε gcc
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
CY1116823T1 (el) Στοχευση abcb5 για θεραπεια καρκινου
CY1117445T1 (el) Παραγωγα φωσφοραμιδικου της 5-φθορο-2´-δεοξυουριδινης για χρηση στην θεραπεια καρκινου
CY1118325T1 (el) Διαλογη αντικαρκινικων ενωσεων μεσω της δραστικοτητας της νετρινης-1
CY1116466T1 (el) Μεθοδος για την προβλεψη αποκρισης σε φαρμακολογικη θεραπευτικη αγωγη σαπερονης των ασθενειων
CY1116089T1 (el) Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων
EA201791843A2 (ru) Способы повышения эффективности folr1 терапии рака
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
CY1111676T1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες